window.dataLayer = window.dataLayer || []; function gtag(){dataLayer.push(arguments);} gtag('js', new Date()); gtag('config', 'G-4PR1PSYQLJ'); Skip to content

Welcome to Discover Pharma! Today is : June 6, 2026

  • News
  • Featured News Archives
    • 12 Days of Christmas
    • Women in Pharma
  • About Us
Contact Us

Central Nervous System

  • Biotech & Pharma Business,Central Nervous System,Clinical & Regulatory

    Newron expands evenamide IP protection with new EU composition of matter patent

    Newron has expanded the intellectual property protection for its lead [...]

    May 5, 2026
  • Central Nervous System,Clinical & Regulatory,Drug Discovery & Development,Pharmaceuticals and therapeutics

    CNS Pharmaceuticals announces primary analysis of Berubicin in second line treatment of glioblastoma multiforme

    CNS Pharmaceuticals has reported the primary analysis of its clinical [...]

    May 5, 2026
  • Central Nervous System,Drug Discovery & Development,Pharmaceuticals and therapeutics,Therapeutic Areas

    Porosome reconstitution therapy reverses Alzheimer’s pathology in human brain organoids

    Porosome Therapeutics has reported preclinical results showing that restoring porosome [...]

    May 5, 2026
  • Biotech & Pharma Business,Central Nervous System,Clinical & Regulatory,Drug Discovery & Development,Therapeutic Areas

    Modulight Biotherapeutics raises $12 million seed funding for optogenetic therapy development

    Modulight Biotherapeutics has raised $12.2 million in a Seed funding [...]

    May 5, 2026
  • Central Nervous System,Clinical & Regulatory,Digital & Data,Therapeutic Areas

    At-home brain stimulation therapy helps prevent depression relapse, study finds

    A major international study has found that remotely supervised, at-home [...]

    May 5, 2026
  • Central Nervous System,Drug Discovery & Development,Pharmaceuticals and therapeutics,Therapeutic Areas

    FDA authorises Emalex Biosciences’ Expanded Access Program for Tourette syndrome drug

    Emalex Biosciences has received FDA authorisation for an Expanded Access [...]

    May 5, 2026
  • Central Nervous System,Clinical & Regulatory,Drug Discovery & Development,Pharmaceuticals and therapeutics

    Celon Pharma receives FDA clearance for Phase 3 trial of CPL’36 in schizophrenia

    Celon Pharma S.A. has received FDA clearance to advance its [...]

    May 5, 2026
  • Central Nervous System,Clinical & Regulatory,Drug Discovery & Development,Medical devices,Pharmaceuticals and therapeutics

    Owlstone Medical awarded up to $49.1 million from ARPA-H to develop at-home multi-cancer early detection tests

    Owlstone Medical has received an award of up to $49.1 [...]

    May 5, 2026
  • Central Nervous System,Clinical & Regulatory,Drug Discovery & Development

    Alto Neuroscience receives FDA Fast Track designation for ALTO-101 to treat cognitive impairment in schizophrenia

    Alto Neuroscience has received FDA Fast Track designation for its [...]

    May 5, 2026
  • Biotech & Pharma Business,Central Nervous System,Drug Delivery & Formulation,Pharmaceuticals and therapeutics,Therapeutic Areas

    Neuraxpharm launches next-generation oral fumarate Riulvy for multiple sclerosis in Germany

    Neuraxpharm Group has launched Riulvy (tegomil fumarate) in Germany, marking [...]

    May 5, 2026
Previous234Next

Bringing you the latest industry news and insights every day

Registered Address: Discover Pharma Ltd, 1 Dartmouth Close, Brighton, BN2 4HZ, UK
Company Number: 16239596

  • About Us
  • Contact Us
  • Legal
    • Cookie Policy
    • Privacy Policy
    • Terms & Conditions
  • Author Guidelines
    • Pharmaceutical Author Guidelines
    • Press Release Advice
  • Advertise with Us
  • Media Kit Request

© 2026 Discover Pharma. All rights reserved • Developed by Hairy Goat Design

Page load link

Press “ESC” key to close

main menu
  • Home
  • News
  • About Us
  • Contact
recent posts
  • Bonito Biosciences partners with DaltonTx on AI-driven RNA delivery research
    Categories: Central Nervous System, Digital & Data, Drug Delivery & Formulation, Drug Discovery & Development, Therapeutic Areas
  • Mestag Therapeutics doses first patient in Phase 1 STARLYS solid tumour trial
    Categories: Biotech & Pharma Business, Clinical & Regulatory, Pharmaceuticals and therapeutics, Therapeutic Areas
  • Protara reports durable 12-month responses for TARA-002 in Phase 2 bladder cancer trial
    Categories: Clinical & Regulatory, Drug Discovery & Development, Pharmaceuticals and therapeutics
get connected
This website uses cookies and third party services. See our Cookie Policy and Privacy Policy pages for details. OK
Go to Top